Nordic Nanovector ASA announces that further to the decisions to discontinue the PARADIGME study for its lead asset Betalutin®, restructure the company and appoint Carnegie Investment Bank to explore strategic options the senior leadership team will be consolidated, and current Chief Executive Officer Erik Skullerud will transition out of his role. Nordic Nanovector's Chief Financial Officer Malene Brondberg will assume the combined position of CFO and interim CEO while the Company continues to work with Carnegie to explore strategic options. The Board has initiated this strategic exercise with the aim of optimising shareholder value, following the slow recruitment and subsequent disappointing data from the PARADIGME clinical trial, while in parallel recognising the need to conserve resources during the process.